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In the last decade, technological advances, new staging tools, better understanding the role of surgery within
multimodal treatment concepts in advanced stages and progress in the functional assessment of surgical candidates
improved the quality of surgery in the management of patients with lung cancer. Lung resection with video-assisted
thoracoscopic access gained wide acceptance, the indication for lobectomy or sublobar resection in early stages was
applied based on new data and selection for multimodal treatment in stage III is better understood based on the data.
A major impact on the outcome of patients with lung cancer has the treatment in specialized high-volume centers.
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Surgery alone or in combination with chemotherapy or
radiotherapy is the cornerstone of lung cancer treatment.
Surgery remains the only or at least most reliable prospect for
cure. Several goals have to be achieved to justify surgery in a
patient with lung cancer. The procedure should result in a
complete resection, the patient should not only survive the
procedure, but also morbidity must be kept as low as possible
and a good quality of life should be maintained. These
principles are known since decades; however, more knowledge
generated from clinical trials, better physiologic understanding,
technological advances and other aspects have clearly improved
the quality of surgical treatment over the last decade.
Furthermore, modern imaging methods including positron
emission tomography—computed tomography, computed
tomography (CT) and magnetic resonance imaging and better
staging including tissue conﬁrmation by endobronchial
ultrasound and mediastinoscopy allow a precise clinical
Tumour–Node–Metastasis staging which is the basis for
treatment planning and deﬁnes the extent as well as the
approach of surgical resection. There is not a single
breakthrough technique developed in the past 10 years which
has revolutionized surgical treatment, but many details have
been improved and the whole spectrum of available new
techniques is implemented in many centers. The higher
complexity of lung cancer treatment and its need for an
individualized medicine has resulted in a formation of
specialized lung cancer treatment centers which may allow
treatment at the highest possible standards.
minimal invasive lobectomies by
video-assisted thoracoscopic surgery
Minimal invasive lobectomies by video-assisted thoracoscopic
surgery (VATS) were introduced 20 years ago. At that time, the
procedure was performed by few surgeons only and it was
debated if VATS resection for lung cancer is an adequate
cancer operation. It was questioned if completeness of
resection is secured and if mediastinal lymphadenectomy is
possible using a minimal invasive approach. Over time more
than 20 comparative studies, two of them were randomized,
could prove that patients with stage I and II lung cancer
treated surgically without a thoracotomy but by VATS had
lower local recurrences and a better 5-year survival. A
systematic review by Yan et al. [1] summarizes the VATS
studies. The excellent cosmetic result of the small incisions and
the rapid recovery of the patient after surgery were
demonstrated in multiple studies, despite there were conﬂicting
results from others showing equal outcomes in terms of air
leaks, atrial ﬁbrillation and bleeding. Once again, these studies
showed that the outcome is dependent on consistent quality of
surgery and the patient selection. Due to the fast recovery of
the patient after surgery and the lesser trauma of surgery, it
was demonstrated by Peterson [2] that adjuvant chemotherapy
was less delayed, less reduced in dosage and more received
>75% of the planned dosage. In the last 10 years, VATS
lobectomy became the treatment of choice for patients with
lung cancer in stage I and II by many, especially younger
surgeons. In some specialized thoracic surgical centers, up to
70% of the patients are resected for lung cancer by VATS. In
the last few years, robotic-assisted lobectomy using the
‘DaVinci’ system was explored in some institutions [3] and its
feasibility has been demonstrated. However, until now it has
not been shown that robotic-assisted surgery has a major
advantage over VATS, mainly due to the fact that some
instruments and especially staplers are not yet available in
robotic surgery but necessary for a save lobectomy.
lobectomy versus sublobar resection
The question if a lobectomy is necessary for an adequate lung
cancer resection in all patients or if a sublobar resection
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(segmentectomy or wedge resection) can be applied in smaller
tumors with at least equally good long-term survival has been
addressed also >20 years ago. In a landmark study, the former
North American lung cancer study group performed a
randomized trial of stage I patients comparing lobectomy with
more limited segmental or wedge resection [4]. The results
showed that patients treated by lobectomy had statistically a
lower local recurrence rate and a trend to better 5-year survival
without reaching the statistical signiﬁcance. This let to the
conclusion that lobectomy is treatment of choice for T1 and
T2 tumors. However, in this study, tumors up to 3 cm and
nonanatomical wedge resections have been included. The role
of anatomic segmentectomy for peripheral T1, N0 tumors was
studied extensively in multiple case series and small
randomized trials mainly in Japan. Several studies showed that
T1 tumors of <2 cm in diameter located in the periphery of the
lobe and resected by a segmentectomy achieve a 5-year survival
rates of 85%–90% [5]. With the implementation of screening
programs by CT and/or the liberal use of CT scans for several
indications, more small cancers are detected. With the correct
indication, segmentectomy became its clear role in lung cancer
treatment and lung sparing procedures are applied, whenever
possible and indicated.
surgery for advanced stages
Surgery for advanced stages within a multidisciplinary concept
has made progress over the last years due to better staging and
hence patient selection, safer surgery and a whole spectrum of
surgical techniques such as sleeve resections [6]. This allowed
achieving long-term survivors even in these advanced cases.
Stage III includes a large variety of clinical situations from
chest wall invasion together with intralobar lymph node
metastasis to any size of a lung cancer in combination with
mediastinal lymph node involvement (N2/N3). Furthermore,
the prognosis of patients with lymph node metastasis depends
largely on the extent of the disease, which may range from
micro-metastasis occasionally found during surgery to bulky
and/or multilevel involvement of the mediastinum or
extracapsular inﬁltration. Not surprisingly, the optimal
treatment including the role of surgery for stage IIIA (N2) and
stage IIIB (T4/N3) nonsmall-cell lung cancer is discussed
controversially. Adequate analysis of the clinical stage is the key
to select the best treatment. In general, patients beneﬁt from
surgery, when a radical resection can be achieved with a low
morbidity and mortality. A multidisciplinary approach is
indicated in most patients, which present with stage III disease
at diagnosis. Preferentially, patients should be treated
according to the study protocols whenever they are available.
Radical surgery including chest wall resection may result in a
5-year survival rate of up to 50% in T3N1 disease. Adjuvant
chemotherapy is recommended and radiotherapy is reserved
for cases with unclear resection margins. Clinical trials of
preoperatively proven N2 patients could show a better outcome
when down-staging is achieved after neoadjuvant chemo- or
chemoradiotherapy before surgery. The patients who may need
pneumonectomy should be selected with caution because some
centers experience a high perioperative mortality rate. If
unforeseen N2 disease is found during surgery, an adjuvant
therapy is recommended. Patients with T4 tumors (inﬁltration
of great vessels, trachea, esophagus, vertebral bodies, etc.) show
an increasing 5-year survival from 15% to 35% after radical
resection with acceptable perioperative mortality if treated in
experienced centers. In stage III nonsmall-cell lung cancer,
surgery should be performed within a multimodality approach.
Surgery should be recommended when resection is radical,
including systematic lymph node dissection and mortality and
morbidity are low.
the role of specialized thoracic surgical
centers
Specialized thoracic surgeons dedicated to the thoracic
oncology ﬁeld and attached to a specialized thoracic surgical
center working closely together with other disciplines have
given a major impact on short-term outcome and also in long-
term survival of patients with lung cancer. Multiple studies
have shown the correlation between the higher volume of
treated cases by a surgeon and by a hospital and a lower
surgical mortality. The SEER Medicare database has evaluated
more than 2000 patients treated in 76 hospitals between 1985
and 1996. The 30-day mortality in low-volume centers (less
than eight procedures per year) was 6% and in high-volume
centers (>67 procedures per year) it was 3%. Even more
impressively are the results from national registry of lung
cancer in Japan where 11 664 cases of lung cancer surgery were
analyzed with a thirty 30-day mortality rate of as low as 0.4%
[7]. In Germany, the hospital mortality in 2008 was 7% in low-
volume centers (<15 resections per year) and 2.4% in high-
volume centers (>180 resections per year). Furthermore, it has
been demonstrated that long-term outcome is also clearly
different for patients treated by a general surgeon versus a
specialized thoracic surgeon since 5-year survival is 7% higher
in stage I and II and 6% in stage III when treated by a thoracic
surgeon [8]. Bach et al. [9] demonstrate a long-term survival
beneﬁt in surgically treated patients with lung cancer based on
the number of cases treated in the hospital. It was not
explained by surgical mortality alone rather than patient
selection and over all treatment. It is most likely that the
treatment of a patient with lung cancer in a specialized, high-
volume center which has all disciplines has one of the most
relevant impacts in overall survival of the patient.
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